PMC8254586_01
Chest CT scan of February 19, 2019 representing a left upper lobe pulmonary nodule of 12.4 mm in lung window (A) and a prevascular adenopathy in mediastinal window of 12.7 mm (B). Chest X-Ray with the cross-sectional height at which pulmonary nodule is located (C).
OTT-14-3949-g0001.jpg
PMC8254586_01_OTT-14-3949-g0001.jpg
f0001
A left upper lobe pulmonary nodule of 12.4 mm was discovered in March 2019 following symptoms of coughing (Figure 1).
Pre-therapeutic TEP scan of March 19, 2019 representing a hypermetabolism of the left upper lobe pulmonary nodule (SUVmax: 3.29) (A and B); and an intense hypermetabolism focus in the left interlobular lymph node (SUVmax: 5.55) (C).
OTT-14-3949-g0002.jpg
PMC8254586_01_OTT-14-3949-g0002.jpg
f0002
A PET scan showed an hypermetabolism of the left upper lobe pulmonary nodule (SUVmax: 3.29) and an intense hypermetabolic focus in the left interlobular lymph node (SUVmax: 5.55) (Figure 2).
CT scan of February 5, 2020 revealing a mediastinal lymph node progression (RECIST 1.1) with a 21 mm adenopathy in front of the aortic arch and a second one of 18 mm in the pretracheal space.
OTT-14-3949-g0003.jpg
PMC8254586_01_OTT-14-3949-g0003.jpg
f0003
In February 2020, the CT scan revealed a mediastinal lymph node progression (RECIST 1.1) with a 21 mm adenopathy in front of the aortic arch and a second one of 18 mm in the pretracheal space (Figure 3).
CT scan of June 11, 2020 showing a partial response aspect (RECIST 1.1) of two mediastinal lymph node involvements, the first in front of the aortic arch (A) and a second one of 18 mm in the pretracheal space (B).
OTT-14-3949-g0004.jpg
PMC8254586_01_OTT-14-3949-g0004.jpg
f0004
CT scan of December 28, 2020 representing a lymph node and pleural progression.
OTT-14-3949-g0005.jpg
PMC8254586_01_OTT-14-3949-g0005.jpg
f0005
In December 2020, 3 months after discontinuation of crizotinib, the patient presented a lymph node and pleural progression (Figure 5).